Pulmatrix IncNASDAQ:PULM
- LAST PRICE3.9900
- TODAY'S CHANGE (%)-0.0200 (-0.4988%)
- Bid / Lots3.9900/ 4
- Ask / Lots4.1600/ 5
- Open / Previous Close4.0300 / 4.0100
- Day Range
- 52 Week Range
- Volume29,048
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PULM |
|---|---|---|
| 09:32 ET | 200 | 4.03 |
| 09:37 ET | 200 | 3.8711 |
| 10:18 ET | 499 | 3.91 |
| 10:33 ET | 100 | 4.06 |
| 10:40 ET | 420 | 4.0566 |
| 10:54 ET | 100 | 4.06 |
| 10:58 ET | 750 | 4.0608 |
| 11:02 ET | 812 | 3.88 |
| 11:36 ET | 800 | 3.9423 |
| 11:38 ET | 200 | 3.9862 |
| 11:48 ET | 550 | 4 |
| 11:52 ET | 200 | 4.02 |
| 11:54 ET | 300 | 4.02 |
| 12:01 ET | 247 | 4.0563 |
| 12:17 ET | 400 | 4.06 |
| 12:21 ET | 1667 | 4.07 |
| 12:24 ET | 130 | 4.0557 |
| 12:26 ET | 500 | 4.07 |
| 12:48 ET | 1007 | 4.07 |
| 12:51 ET | 200 | 4.06 |
| 12:55 ET | 500 | 4.0899 |
| 01:06 ET | 100 | 4.07 |
| 01:18 ET | 3004 | 4.1499 |
| 01:20 ET | 200 | 4.14 |
| 01:24 ET | 1500 | 4.1201 |
| 01:26 ET | 248 | 4.12 |
| 01:27 ET | 500 | 4.1342 |
| 01:40 ET | 100 | 4.14 |
| 01:42 ET | 100 | 4.14 |
| 01:49 ET | 100 | 4.14 |
| 01:51 ET | 200 | 4.13 |
| 01:54 ET | 1100 | 4.14 |
| 01:58 ET | 3000 | 4.1201 |
| 02:00 ET | 600 | 4.15 |
| 02:14 ET | 100 | 4.14 |
| 02:32 ET | 293 | 4.1327 |
| 02:39 ET | 200 | 4.16 |
| 02:43 ET | 100 | 4.16 |
| 02:56 ET | 400 | 4.135 |
| 03:03 ET | 1600 | 4.1207 |
| 03:10 ET | 232 | 4.085 |
| 03:32 ET | 900 | 4.095 |
| 03:35 ET | 300 | 4.07 |
| 03:39 ET | 200 | 4.06 |
| 03:51 ET | 100 | 4.015 |
| 03:55 ET | 800 | 4.0699 |
| 04:00 ET | 881 | 3.99 |
Jan 4, 2023
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment, from 10:44AM ET on Wednesday Jan 04, 2023 by MT Newswires
10:44AM ET on Wednesday Jan 04, 2023 by MT NewswiresBRIEF-Pulmatrix Announces Positive Top Line Results From Phase 1 Study With PUR3100, from 9:06AM ET on Wednesday Jan 04, 2023 by Thomson Reuters
9:06AM ET on Wednesday Jan 04, 2023 by Thomson Reuters
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pulmatrix Inc | 14.6M | -0.6x | --- |
Athersys Inc | 17.1M | -0.2x | --- |
Aeterna Zentaris Inc | 18.1M | -1.7x | --- |
Erytech Pharma SA | 17.4M | 0.0x | --- |
Agile Therapeutics Inc | 12.1M | 0.0x | --- |
Bellicum Pharmaceuticals Inc | 11.2M | -2.6x | --- |
Company Information
Pulmatrix, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs. It designs and develops inhaled therapeutic products based on its dry powder delivery technology, inhaled small particles easily respirable and emitted (iSPERSE), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE’s lead development program, Pulmazole is its inhaled formulation of itraconazole, an anti-fungal drug commercially available as an oral drug, which it is developing to treat and prevent pulmonary fungal infections. PUR1800 is developing for the treatment of acute exacerbations of chronic obstructive pulmonary disease and PUR3100 is developing for the treatment of acute migraine.
Contact Information
- Headquarters
- 99 Hayden Ave Ste 390LEXINGTON, MA, United States 02421-7966
- Phone
- 781-357-2333
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Michael Higgins
- President, Chief Executive Officer, Director
- Teofilo Raad
- Interim Chief Financial Officer
- Peter Ludlum
- Vice President - Finance
- Michelle Siegert
- Chief Medical Officer
- Margaret Wasilewski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.6M |
|---|---|
Revenue (TTM) | $4.8M |
Shares Outstanding | 3.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-6.84 |
Book Value | $14.73 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -387.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
